Prof Pepys’s persistence pays off

Sometimes in science, persistence is rewarded. For more than 30 years Mark Pepys, professor of medicine at University College London, has concentrated on research into amyloidosis, an incurable disease that causes organ failure in tens of thousands of people a year worldwide.

Amyloidosis is caused by the build up of abnormal “amyloid” proteins in body tissues. Prof Pepys has long believed that the key to understanding the disease is a related blood protein called SAP, which sticks to amyloid fibres and stops enzymes removing them.

The FT has covered his work several times. My predecessor David Fishlock described in 1990 Prof Pepys’s discovery of a way to image SAP and amyloid fibres. I wrote in 1995 and 2002 about progress in developing a drug called CPHPC, which aimed to clear the destructive amyloid deposits from patients by removing the protective SAP from their blood.

Prof Pepys was working then in collaboration with Roche. But the Swiss pharmaceutical giant eventually pulled out.

“While we had promising early results [with CPHPC] they were not enough to benefit patients with advanced disease,” he says. “Something more dramatic is needed.”

That something turns out to a combination of CPHPC with an antibody – a molecular guidance system designed to seek out amyloid deposits in vital organs.

Now Prof Pepys has reached an agreement with another big pharmaceutical group, UK-based GlaxoSmithKline, to collaborate on producing a treatment for amyloidosis based on the CPHPC-antibody combination.

Although the details of this week’s deal are confidential, Prof Pepys says GSK will spend many millions of pounds working with UCL scientists, to convert their successful animal tests into an antibody-based drug for human use.

Mike Owen, GSK’s head of biopharmaceutical research, said it was realistic to aim for clinical trials within two years.

Symptoms of amyloidosis are very variable because the heart, kidneys, liver and almost any other organ can be affected. Every year 500 to 1,000 new cases are diagnosed in the UK, mainly in middle-aged and older people; their prognosis is poor.

Although amyloidosis is a rare disease, there are enough sufferers – an estimated 80,000 in the industrialised world – to bring in considerable revenues from an effective drug.

Prof Pepys points out that antibody-based medicines can sell for tens of thousands of pounds per patient, particularly if they treat a previously untreatable disease.

While staff at GSK’s research centre in Stevenage will look after the clinical development of the new medicine, “Prof Pepys will remain closely involved in the project,” says Pauline Williams, the company’s head of academic liaison. “It was critical for him to feel that he was not handing everything over to us.”

The world of research

The science blog is no longer updated but it remains open as an archive.

Clive Cookson, the FT's science editor, picks out the research that everyone should know about, in fields from astronomy to zoology. He also discusses key policy issues, from R&D funding to science education. He'll cover the weird and wonderful, as well as the serious side of science.

The FT’s Science blog: a guide

Comment: To comment, please register with FT.com, which you can do for free here. Please also read our comments policy here.
Contact: You can write to Clive using this email format: firstname.surname@ft.com
Time: UK time is shown on posts.
Follow: Links to the blog's Twitter and RSS feeds are at the top of the page. You can also read the Science blog on your mobile device, by going to www.ft.com/scienceblog

Full list of FT blogs

Featured blogs

Health blog

Dr Margaret McCartney and others discuss the future of healthcare

Tech blog

Dispatches from the FT's San Francisco experts